Contreras-GarcÃa, I.J.; Gómez-Lira, G.; Phillips-Farfán, B.V.; Pichardo-MacÃas, L.A.; GarcÃa-Cruz, M.E.; Chávez-Pacheco, J.L.; Mendoza-Torreblanca, J.G.
Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Brain Sci. 2021, 11, 531.
https://doi.org/10.3390/brainsci11050531
AMA Style
Contreras-GarcÃa IJ, Gómez-Lira G, Phillips-Farfán BV, Pichardo-MacÃas LA, GarcÃa-Cruz ME, Chávez-Pacheco JL, Mendoza-Torreblanca JG.
Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Brain Sciences. 2021; 11(5):531.
https://doi.org/10.3390/brainsci11050531
Chicago/Turabian Style
Contreras-GarcÃa, Itzel Jatziri, Gisela Gómez-Lira, Bryan VÃctor Phillips-Farfán, Luz Adriana Pichardo-MacÃas, Mercedes Edna GarcÃa-Cruz, Juan Luis Chávez-Pacheco, and Julieta G. Mendoza-Torreblanca.
2021. "Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment" Brain Sciences 11, no. 5: 531.
https://doi.org/10.3390/brainsci11050531
APA Style
Contreras-GarcÃa, I. J., Gómez-Lira, G., Phillips-Farfán, B. V., Pichardo-MacÃas, L. A., GarcÃa-Cruz, M. E., Chávez-Pacheco, J. L., & Mendoza-Torreblanca, J. G.
(2021). Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Brain Sciences, 11(5), 531.
https://doi.org/10.3390/brainsci11050531